Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SDZ.SW
- Price
- 55.92
- Stock movement up
- +0.32 (0.58%)
- Company name
- Sandoz Group AG
- Exchange
- (SW ,
- Currency
- CHF )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 24.08B
- Ent value
- 35.49B
- Price/Sales
- 1.42
- Price/Book
- 2.73
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 53.28
- Forward P/E
- 13.99
- PEG
- -
- EPS growth
- -
- 1 year return
- 40.26%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-11-25
DIVIDENDS
SDZ.SW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 53.28 |
| Price to OCF | 18.62 |
| Price to FCF | 58.46 |
| Price to EBITDA | 23.77 |
| EV to EBITDA | 35.01 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.42 |
| Price to Book | 2.73 |
| EV to Sales | 2.10 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 430.70M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | 4.00 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.39B |
| Net receivables | 2.69B |
| Total current assets | 8.37B |
| Goodwill | 7.98B |
| Intangible assets | 1.68B |
| Property, plant and equipment | 0.00 |
| Total assets | 21.61B |
| Accounts payable | 1.75B |
| Short/Current long term debt | 5.69B |
| Total current liabilities | 6.48B |
| Total liabilities | 12.79B |
| Shareholder's equity | 8.82B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 55.84 |
| Daily high | 56.20 |
| Daily low | 55.20 |
| Daily Volume | 655K |
| All-time high | 55.92 |
| 1y analyst estimate | 51.80 |
| Beta | 0.27 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | 17 Apr 2025 |
| Next earnings date | 25 Feb 2026 |
Downside potential
Loading...
Downside potential data
| SDZ.SW | S&P500 | |
| Current price drop from All-time high | -1.12% | -4.13% |
| Highest price drop | -32.15% | -19.00% |
| Date of highest drop | 9 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -6.46% | -2.73% |
| Avg time to new high | 8 days | 6 days |
| Max time to new high | 102 days | 89 days |
COMPANY DETAILS
Marketcap
24.08B
Marketcap category
Large-cap
Description
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
Employees
20000
Website
Investor relations
-
SEC filings
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
On November 12, 2025, EirGenix Inc. announced a global license agreement granting Sandoz Group exclusive worldwide commercial rights (excluding select Asian markets) to a proposed biosimilar of oncolo...
November 20, 2025
Ever wondered if Sandoz Group stock could be a hidden value play, or if you're just jumping in after the most exciting moves? Let's find out what might actually be under the hood. After a rocky 2.4% d...
November 20, 2025
The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despi...
November 19, 2025
The global renal anemia market is experiencing significant growth, driven by advancements in therapeutic options, increased diagnostic accuracy, and enhanced healthcare investments in the U.S., Europe...
November 18, 2025
AMSTERDAM, November 17, 2025--Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now...
November 17, 2025
Canada will be the first regulated market to undergo a market influx of semaglutide biosimilars.
November 12, 2025
Sandoz Group (SWX:SDZ) has secured exclusive global rights to commercialize a biosimilar version of pertuzumab, following a milestone-based agreement with EirGenix Inc. This move signals a meaningful ...
November 12, 2025
Market opportunities in the Pulmonary Arterial Hypertension (PAH) sector include increased demand for innovative therapies due to rising PAH prevalence and greater awareness, alongside enhanced diagno...
November 11, 2025
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerati...
November 5, 2025
Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology Accelerated implementation of strateg...
November 4, 2025
Next page